Cargando…

Receptor-binding domain-specific human neutralizing monoclonal antibodies against SARS-CoV and SARS-CoV-2

The outbreaks of severe acute respiratory syndrome (SARS) and Coronavirus Disease 2019 (COVID-19) caused by SARS-CoV and SARS-CoV-2, respectively, have posed severe threats to global public health and the economy. Treatment and prevention of these viral diseases call for the research and development...

Descripción completa

Detalles Bibliográficos
Autores principales:	Yu, Fei, Xiang, Rong, Deng, Xiaoqian, Wang, Lili, Yu, Zhengsen, Tian, Shijun, Liang, Ruiying, Li, Yanbai, Ying, Tianlei, Jiang, Shibo
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2020
Materias:	Review Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7506210/ https://www.ncbi.nlm.nih.gov/pubmed/32963228 http://dx.doi.org/10.1038/s41392-020-00318-0

Ejemplares similares

Recent advances in developing small-molecule inhibitors against SARS-CoV-2
por: Xiang, Rong, et al.
Publicado: (2022)

Influenza virus glycoprotein-reactive human monoclonal antibodies
por: Li, Yanbai, et al.
Publicado: (2020)

Identification of SARS-CoV RBD-targeting monoclonal antibodies with cross-reactive or neutralizing activity against SARS-CoV-2
por: Tai, Wanbo, et al.
Publicado: (2020)

A monoclonal antibody that neutralizes SARS-CoV-2 variants, SARS-CoV, and other sarbecoviruses
por: Wang, Pengfei, et al.
Publicado: (2021)

A monoclonal antibody that neutralizes SARS-CoV-2 variants, SARS-CoV, and other sarbecoviruses
por: Wang, Pengfei, et al.
Publicado: (2021)

Development of human neutralizing monoclonal antibodies for prevention and therapy of MERS-CoV infections
por: Ying, Tianlei, et al.
Publicado: (2015)

Development of Small-Molecule MERS-CoV Inhibitors
por: Liang, Ruiying, et al.
Publicado: (2018)

Immunization with the receptor-binding domain of SARS-CoV-2 elicits antibodies cross-neutralizing SARS-CoV-2 and SARS-CoV without antibody-dependent enhancement
por: Zang, Jinkai, et al.
Publicado: (2020)

Identification of Human Single-Domain Antibodies against SARS-CoV-2
por: Wu, Yanling, et al.
Publicado: (2020)

Broad neutralization of SARS-CoV-2 variants by an inhalable bispecific single-domain antibody
por: Li, Cheng, et al.
Publicado: (2022)

Identification and characterization of novel neutralizing epitopes in the receptor-binding domain of SARS-CoV spike protein: Revealing the critical antigenic determinants in inactivated SARS-CoV vaccine
por: He, Yuxian, et al.
Publicado: (2006)

The impact of receptor-binding domain natural mutations on antibody recognition of SARS-CoV-2
por: Li, Cheng, et al.
Publicado: (2021)

Human-IgG-Neutralizing Monoclonal Antibodies Block the SARS-CoV-2 Infection
por: Wan, Jinkai, et al.
Publicado: (2020)

Structural insights into the cross-neutralization of SARS-CoV and SARS-CoV-2 by the human monoclonal antibody 47D11
por: Fedry, Juliette, et al.
Publicado: (2021)

Neutralizing SARS-CoV-2
por: Poeschla, Eric
Publicado: (2020)

Antibody Cocktail Exhibits Broad Neutralization Activity Against SARS-CoV-2 and SARS-CoV-2 Variants
por: Qu, Yuanyuan, et al.
Publicado: (2021)

Recognition of the SARS-CoV-2 receptor binding domain by neutralizing antibodies
por: Yuan, Meng, et al.
Publicado: (2021)

Anti-SARS-CoV-2 neutralizing monoclonal antibodies: clinical pipeline
por: Tuccori, Marco, et al.
Publicado: (2020)

Development and characterization of SARS-CoV-2 variant-neutralizing monoclonal antibodies
por: Qiu, Hongyu, et al.
Publicado: (2021)

On the interactions of the receptor-binding domain of SARS-CoV-1 and SARS-CoV-2 spike proteins with monoclonal antibodies and the receptor ACE2
por: Corrêa Giron, Carolina, et al.
Publicado: (2020)

SARS-COV-2 recombinant Receptor-Binding-Domain (RBD) induces neutralizing antibodies against variant strains of SARS-CoV-2 and SARS-CoV-1
por: Law, John Lok Man, et al.
Publicado: (2021)

Antibodies induced by receptor-binding domain in spike protein of SARS-CoV do not cross-neutralize the novel human coronavirus hCoV-EMC
por: Du, Lanying, et al.
Publicado: (2013)

Neutralizing Antibodies against SARS-CoV-2 and Other Human Coronaviruses
por: Jiang, Shibo, et al.
Publicado: (2020)

Characterization of MW06, a human monoclonal antibody with cross-neutralization activity against both SARS-CoV-2 and SARS-CoV
por: Jiang, Wen, et al.
Publicado: (2021)

Potent SARS-CoV-2 binding and neutralization through maturation of iconic SARS-CoV-1 antibodies
por: Rouet, Romain, et al.
Publicado: (2021)

Humanized single domain antibodies neutralize SARS-CoV-2 by targeting the spike receptor binding domain
por: Chi, Xiaojing, et al.
Publicado: (2020)

Comparison and Analysis of Neutralizing Antibody Levels in Serum after Inoculating with SARS-CoV-2, MERS-CoV, or SARS-CoV Vaccines in Humans
por: Yu, Sicong, et al.
Publicado: (2021)

Potential recombination between SARS-CoV-2 and MERS-CoV: calls for the development of Pan-CoV vaccines
por: Wang, Qiao, et al.
Publicado: (2023)

Binding and neutralizing abilities of antibodies towards SARS-CoV-2 S2 domain
por: Gao, Xingsu, et al.
Publicado: (2022)

Broadly neutralizing antibodies to SARS-CoV-2 and other human coronaviruses
por: Chen, Yanjia, et al.
Publicado: (2022)

Structural basis for neutralization of SARS-CoV-2 and SARS-CoV by a potent therapeutic antibody
por: Lv, Zhe, et al.
Publicado: (2020)

Duration of serum neutralizing antibodies for SARS-CoV-2: Lessons from SARS-CoV infection
por: Lin, Qingqing, et al.
Publicado: (2020)

B cell genomics behind cross-neutralization of SARS-CoV-2 variants and SARS-CoV
por: Scheid, Johannes F., et al.
Publicado: (2021)

A highly conserved cryptic epitope in the receptor binding domains of SARS-CoV-2 and SARS-CoV
por: Yuan, Meng, et al.
Publicado: (2020)

The neutralizing breadth of antibodies targeting diverse conserved epitopes between SARS-CoV and SARS-CoV-2
por: Xiong, Hualong, et al.
Publicado: (2022)

The role of single-domain antibodies (or nanobodies) in SARS-CoV-2 neutralization
por: Zebardast, Arghavan, et al.
Publicado: (2021)

Neutralizing and protective human monoclonal antibodies recognizing the N-terminal domain of the SARS-CoV-2 spike protein
por: Suryadevara, Naveenchandra, et al.
Publicado: (2021)

Induction of neutralizing antibodies against SARS-CoV-2 variants by a multivalent mRNA-lipid nanoparticle vaccine encoding SARS-CoV-2/SARS-CoV Spike protein receptor-binding domains
por: Zhang, Qiong, et al.
Publicado: (2022)

Neutralization or enhancement of SARS-CoV-2 infection by a monoclonal antibody targeting a specific epitope in the spike receptor-binding domain
por: Lai, Guan-Chun, et al.
Publicado: (2022)

The Comparative Immunological Characteristics of SARS-CoV, MERS-CoV, and SARS-CoV-2 Coronavirus Infections
por: Zhang, Yun-yu, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_mn0iq83b3p6ets4062s7l31343